Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
Cornelia De Lange Syndrome
|
0.210 |
Biomarker
|
disease |
BEFREE |
Pds5B mutant mice have developmental abnormalities resembling CdLS; however the role of Pds5A in mammals and the association of PDS5 proteins with CdLS are unknown.
|
19412548 |
2009 |
Cornelia De Lange Syndrome
|
0.210 |
Biomarker
|
disease |
MGD |
|
|
|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Red blood cell distribution width: Genetic evidence for aging pathways in 116,666 volunteers.
|
28957414 |
2017 |
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Red blood cell distribution width: Genetic evidence for aging pathways in 116,666 volunteers.
|
28957414 |
2017 |
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis.
|
19503088 |
2009 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Indeed, an immunohistochemical analysis of early-stage ESCC showed that carcinoma cells expressing FGFR3IIIc stained positively with SCC-112, a tumor marker, and Ki67, a cell proliferation marker, suggesting that the expression of FGFR3IIIc promotes cell proliferation.
|
26487184 |
2016 |
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Although the mechanism by which Pds5A functions in GBM cells remains unclear, its overexpression in high grade gliomas implies that it could play a pivotal role during the development and progression of astrocytic tumors.
|
21069257 |
2011 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Suggesting the complex role of SCC-112 might be existent in cell proliferation and tumor development.
|
17846787 |
2008 |
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Indeed, an immunohistochemical analysis of early-stage ESCC showed that carcinoma cells expressing FGFR3IIIc stained positively with SCC-112, a tumor marker, and Ki67, a cell proliferation marker, suggesting that the expression of FGFR3IIIc promotes cell proliferation.
|
26487184 |
2016 |
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
While Pds5A(-/-) and Pds5B(-/-) mice die at birth, embryos harboring 3 mutant Pds5 alleles die between E11.5 and E12.5 most likely of heart failure, indicating that total Pds5 gene dosage is critical for normal development.
|
19412548 |
2009 |
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
While Pds5A(-/-) and Pds5B(-/-) mice die at birth, embryos harboring 3 mutant Pds5 alleles die between E11.5 and E12.5 most likely of heart failure, indicating that total Pds5 gene dosage is critical for normal development.
|
19412548 |
2009 |
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
SCC-112 gene is involved in tumor progression and promotes the cell proliferation in G2/M phase.
|
17846787 |
2008 |
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
This study is attempted to explore the role of SCC-112 in tumorigenesis.
|
17846787 |
2008 |
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Stable transfection of SCC-112 cDNA in MDA-MB 231 breast cancer cells also led to an increase in the number of cells in sub-G1 phase ( approximately 2-3-fold), indicative of apoptosis.
|
15019998 |
2004 |
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
SCC-112, a novel cell cycle-regulated molecule, exhibits reduced expression in human renal carcinomas.
|
15019998 |
2004 |
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Stable transfection of SCC-112 cDNA in MDA-MB 231 breast cancer cells also led to an increase in the number of cells in sub-G1 phase ( approximately 2-3-fold), indicative of apoptosis.
|
15019998 |
2004 |